G-1 is a selective and potent agonist against the GPR30 receptor, an estradiol binding receptor that contributes to both uterine and neurological responses.
G-1 inhibits the production of lipopolysaccharide （LPS） induced cytokines such as IL-6 and TNF-alpha.
It is also reported to block MCF-1 cell cycle progression at the G1 phase and display therapeutic effects in multiple sclerosis models.
